Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERO-19: Edoxaban in COVID-19
NCT04542408Phase 3Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Nov 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of edoxaban in coronavirus disease 2019 (COVID-19), sponsored by University Medical Center Hamburg-Eppendorf. Started Nov 2020; status: completed.
02
Drugs
edoxaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04542408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542408.